$165.31
Value $16.6B
NBIX and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$165.31
Value $16.6B
$691.33
Value $257B
Neurocrine Biosciences (NBIX) has a market value of $16.6B and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, NBIX moved +14.1% and TMO +19.9%. The P/E is 23.6 for NBIX and 36.3 for TMO. Dividend yield: NBIX none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
NBIX$16.6B
TMO$257B
TMO is 15 times NBIX
Revenue, 12 months
NBIX$3.7B
TMO$47.4B
TMO is 13 times NBIX
Net income, 12 months
NBIX$703M
TMO$7.1B
TMO is 10 times NBIX
Operating margin
NBIX24.0%
TMO17.9%
6.1 points apart
ROIC
NBIX19.4%
TMO8.2%
11.2 points apart
P/E
NBIX23.6
TMO36.3
TMO is 1.5 times NBIX
Dividend yield
NBIX0.0%
TMO0.3%
0.3 points apart
5-year return
NBIX+88.3%
TMO+10.9%
77.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
NBIX+88.3%
TMO+10.9%
| Period | NBIXWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +14.1%Price +14.1% | +19.9%Price +19.5% |
| 3 years since November 16, 2023 | +52.0%+15.0% a yearPrice +52.0% | +47.7%+13.9% a yearPrice +46.3% |
| 5 years since November 15, 2021 | +88.3%+13.5% a yearPrice +88.3% | +10.9%+2.1% a yearPrice +9.3% |
| 10 years since November 16, 2016 | +222.0%+12.4% a yearPrice +222.0% | +375.7%+16.9% a yearPrice +362.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
NBIXNeurocrine BiosciencesTMOThermo Fisher Scientific
| Price | $165.31 | $691.33 |
|---|---|---|
| Market value | $16.6B | $257B |
| Enterprise value (EV) | $15.9B | $292B |
| P/E | 23.6 | 36.3 |
| P/E, 5-year median | 53.3 | 32.7 |
| P/B | 4.3 | 4.7 |
| EV/EBIT | 17.9 | 34.5 |
| Free cash flow yield | 6.3% | 3.0% |
| Revenue, 12 months | $3.7B | $47.4B |
|---|---|---|
| Net income, 12 months | $703M | $7.1B |
| Free cash flow, 12 months | $1.0B | $7.6B |
| Earnings per share, 12 months | $6.74 | $18.96 |
| Revenue growth, year on year | 21.5% | 3.9% |
| Revenue growth a year, past | +22.3%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | +2.3%over 5 years | +2.1%over 5 years |
| Gross margin | 97.8% | – |
|---|---|---|
| Operating margin | 24.0% | 17.9% |
| Net margin | 19.0% | 14.9% |
| ROIC | 19.4% | 8.2% |
| ROE | 20.4% | 13.4% |
| Cash | $738M | $6.1B |
|---|---|---|
| Total debt | $452M | $41.4B |
| Net debt / EBITDA | -0.8 | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | 1.0% | 1.2% |
| Shareholder yield | 1.0% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 15.5 times Neurocrine Biosciences ($16.6B), at today's prices.
Since November 16, 2016, NBIX's price moved +222.0% and TMO's +362.5%. With dividends: NBIX +222.0% (+12.4% a year), TMO +375.7% (+16.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Neurocrine Biosciences and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
At today's price, the P/E is 23.6 for NBIX and 36.3 for TMO. The median of the last five years was 53.3 and 32.7, which shows where each stands against its own past.
Over the last twelve months, the net margin was 19.0% for Neurocrine Biosciences and 14.9% for Thermo Fisher Scientific, and the operating margin 24.0% and 17.9%. Revenue was $3.7B and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.